GSK gets option to OncoMed's cancer stem cell antibodies; terminated
GlaxoSmithKline's Center of Excellence for External Drug Discovery has agreed to option four of start-up OncoMed Pharmaceuticals's monoclonal antibodies--including lead OMP21M18 in preclinical studies--against cancer stem cells.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com